Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response

Published:2024-07-10 Issue:20 Volume:42 Page:2372-2376
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Valenza Carmine¹²^ORCID,Trapani Dario¹²^ORCID,Loibl Sibylle³^ORCID,Chia Stephen K.L.⁴,Burstein Harold J.⁵⁶⁷^ORCID,Curigliano Giuseppe¹²^ORCID

Affiliation:

1. Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy

2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

3. Center for Hematology and Oncology Bethanien, Frankfurt, Germany

4. BC Cancer Agency, Vancouver, BC, Canada

5. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

6. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA

7. Harvard Medical School, Boston, MA

Abstract

pCR should be integrated with other prognostic factors to optimize postneoadjuvant treatments in BC.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01935

Reference41 articles.

1. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

2. Pembrolizumab for Early Triple-Negative Breast Cancer

3. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

5. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3